Luis Hidalgo, PhD, D(ABHI)
Associate Professor
- Histocompatibility Lab Director
- Division of Transplantation
hidalgo@surgery.wisc.edu
(608) 265-0428
HLA Lab
448 Science Drive
Madison WI 53711
Education
- PhD, Immunology, University of Alberta, 2005
- Diplomate - American Board of Histocompatibility and Immunogenetics, 2012
Research Interests
The focus of my research laboratory aims at elucidating the various mechanisms used by the human immune system to damage transplanted organs with specific focus on antibody-mediated rejection (ABMR). The immunologic understanding of ABMR that we have thus far identified points to a limited number of players. These players include donor-specific antibodies (DSA) (primarily targeting HLA), endothelial cell targets, and NK cell and monocyte effector cells working in concert to maximize their damage.
The laboratory’s projects are therefore split into two principal areas: immune effector cells in ABMR, and endothelial cell biology. The immune effector projects have a strong focus on assessing immune function of NK cells and monocytes particularly as it relates to activation through their Fc-gamma receptors. Endothelial cell studies relate to endothelial susceptibility to immune damage in ABMR and regulation of HLA surface expression. Findings within either of these areas have clinical implications as all of our studies are based on human immunology using primary cells. Our ultimate goal is to identify donor and recipient characteristics that define immunologic risk beyond the limited characteristics currently used.
Recent Publications
Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study.
Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Gauthier P, Billings P, Lawrence C, Lowe D, Hidalgo LG, the Trifecta Investigators
Transplantation 2023 Mar 01; 107(3): 709-719
[PubMed ID: 36190186]Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients: Treatment Response Rates and Value of Early Surveillance Biopsies.
Aziz F, Parajuli S, Jorgenson M, Garg N, Manchala V, Yousif E, Mandelbrot D, Hidalgo L, Mohamed M, Zhong W, Djamali A
Transplant Direct 2022 Sep; 8(9): e1360
[PubMed ID: 35935024]Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes.
Halloran PF, Madill-Thomsen KS, Pon S, Sikosana MLN, Böhmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, Hidalgo LG, Myslak M, Viklicky O, Perkowska-Ptasinska A, INTERCOMEX Investigators
Am J Transplant 2022 Aug; 22(8): 1976-1991
[PubMed ID: 35575435]Factors affecting sensitization following kidney allograft failure.
Garg N, Viney K, Burger J, Hidalgo L, Parajuli S, Aziz F, Mohamed MA, Djamali A, Mandelbrot DA
Clin Transplant 2022 Mar; 36(3): e14558
[PubMed ID: 34923658]Impact of low-level pretransplant donor-specific antibodies on outcomes after kidney transplantation.
Parajuli S, Bath NM, Hidalgo L, Leverson G, Garg N, R Redfield R, Mandelbrot DA
Immun Inflamm Dis 2021 Dec; 9(4): 1508-1519
[PubMed ID: 34407300]